Form 4: Shattuck Labs Officer Buys Stock and Warrants

Shattuck Labs Chief Technical Officer Abhinav A. Shukla acquired company stock and warrants through a private placement.

Summary

• Abhinav A. Shukla, Chief Technical Officer of Shattuck Labs, Inc., acquired 5,122 shares of common stock and accompanying warrants on May 21, 2026.
• The acquisition was part of a private placement that closed on August 25, 2025, with a combined price of $0.8677 per share and warrant.
• The warrants are exercisable until 30 days after the public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety data, and the design of planned Phase 2 trials.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to an insider purchase, indicating management confidence, but the value is tied to future clinical trial success.

Positives

• Insider purchase of company stock and warrants by a key executive (Chief Technical Officer).
• The purchase indicates confidence from management in the company's prospects, particularly related to the SL-325 clinical trial.

Negatives

• The filing does not disclose any negative financial or operational information.

Risks

• The exercise of warrants is contingent on the public announcement of clinical trial data, which may be delayed or not meet expectations.
• The value of the acquired securities is directly tied to the success of the SL-325 clinical trial and future development phases.

Future Outlook

The future outlook for the acquired warrants is dependent on the successful completion and announcement of Phase 1 clinical trial data for SL-325 and the subsequent design of Phase 2 trials.

Industry Context

StockSavvy.ai notes that insider purchases, especially by technical officers, can signal strong conviction in a company's drug development pipeline, particularly in the biotechnology sector where clinical trial outcomes are paramount.

Stakeholder Impact

• Shareholders: The purchase by a key executive may be viewed positively, suggesting internal confidence in the company's future prospects.
• Employees: May be motivated by seeing leadership invest in the company.
• Creditors: No direct impact indicated.

Next Steps

• Public announcement of data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325.
• Public announcement of receptor occupancy and safety data from the Phase 1 trial.
• Public announcement of the design of the planned Phase 2 clinical trial(s).
• Warrants become exercisable 30 days following the public announcement of the aforementioned clinical trial data and Phase 2 design.

Key Dates

Recommendation

The filing indicates an insider purchase, which is generally a positive signal. However, the purchase is of stock and warrants with exercise contingent on clinical trial results. Without more information on the trial's progress or broader company financials, a 'hold' recommendation is prudent, awaiting further developments.

Keywords

Shattuck Labs, STTK, Form 4, Insider Trading, Stock Purchase, Warrants, Clinical Trial, SL-325, Phase 1, Phase 2, Private Placement, Abhinav Shukla